PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Medigene AG

25.03.2003 – 22:06

Medigene AG

euro adhoc: MediGene AG
MediGene discontinues development of CVLP tumor vaccine (E)

Disclosure announcement transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.
Martinsried/San Diego, March 25, 2003. The biopharmaceutical company
MediGene AG (TechDax30: MDG) will discontinue the development project
of a CVLP tumor vaccine against cervical cancer. The data obtained
from a clinical phase 1/2 trial with the vaccine demonstrates very
good tolerability and indicates efficacy. However, the results did
not fulfil the high efficacy criteria (efficacy in 90 % of the
patients) predefined for the continuation of the project.
In the phase 1/2 trial, 36 patients received two different dosages of
the vaccine or placebo and were monitored for 24 weeks. During this
period, only slight side effects occurred and the treatment was very
well tolerated. The evaluation of the immunological data revealed
preliminary efficacy trends (higher T-cell response and antibody
reaction when treated with the vaccine). The morphological data did
not show a significantly increased efficacy in comparison to the
placebo group.
The CVLP project was developed in cooperation with Schering AG, which
contributed to the development costs. For MediGene, the
discontinuation of this cooperation will result in an additional
financial burden of approx. EUR 500,000 in the second half of 2003
that will be balanced out by means of appropriate cost-cutting
measures.
end of announcement        euro adhoc 25.03.2003

Further inquiry note:

Michael Nettersheim Tel.: +49 (0)89 8565 2946 E-Mail: m.nettersheim@medigene.com

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: Nemax 50, Prime Standard, TecDAX
Börsen: Frankfurter Wertpapierbörse / Neuer Markt
Baden-Württembergische Wertpapierbörse / free trade
Bayerische Börse / free trade
Berliner Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Hamburger Wertpapierbörse / free trade
Niedersächsische Börse zu Hannover / free trade

Original content of: Medigene AG, transmitted by news aktuell